Prostate Biopsy News and Research

RSS

The prostate is a small gland that wraps around the urethra, at the base of the urinary bladder. It produces semen, the fluid vehicle of spermatozoa. A biopsy of the prostate is a procedure in which a small sample of prostate tissue is removed in order to examine it, usually in search for signs of malignant transformation of prostate cells.

UIC study reveals potential of lycopene in prostate cancer prevention among African American men

Lycopene, a red pigment that gives tomatoes and certain other fruits and vegetables their color, could help prevent prostate cancer, especially in African American men, according to new research at the University of Illinois at Chicago.

14 Jul 2011

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported the issuance of a new U.S. patent, which represents a significant addition to DiagnoCure's PCA3 prostate cancer biomarker portfolio.

16 Jun 2011

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive licensing agreement with QDx Pathology Services to develop, market and process the QPredict™ Prostate Mitomic Test.

19 May 2011

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

Targeted biopsy, a major advance in prostate cancer diagnostics, was detailed by a UCLA team in the current issue of Urologic Oncology. The new technology fuses MRI with real-time 3D ultrasound, providing an exacting method to obtain biopsy specimens from suspicious areas in the prostate.

12 May 2011

Men with high DHA levels may face risk of developing aggressive prostate cancer

The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.

26 Apr 2011

Mitomics introduces new test to detect prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, announced today the launch of its flagship product, the Prostate Core Mitomic Test, a revolutionary new test that uses the science of mitochondrial DNA to accurately determine the absence or presence of cancerous cells using previously obtained prostate biopsy tissue.

1 Apr 2011

Prostate Oncology Specialists introduces new blog for patients

Prostate Oncology Specialists, Inc. announces the launch of the "Prostate Snatchers" blog. It features contributions from a medical oncologist, Mark Scholz MD, who specializes only in prostate cancer and a prostate cancer patient, Ralph H. Blum.

30 Mar 2011

Debate continues regarding certain medical tests

News outlets report on how discussion continues to swirl around the use of the so-called "PSA velocity" test and mammography guidelines.

8 Mar 2011

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

As a world leader in the advancement of the detection and treatment of prostate cancer, the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center is the first medical facility in the Northeast to install ei-Nav|Artemis™, an innovative image guidance and navigation system for prostate biopsy that is manufactured by Eigen.

25 Feb 2011

Study shows dogs can be trained to detect PCa by smelling urine

In the February 2011 issue of European Urology, Jean-Nicolas Cornu and colleagues reported the evaluation of the efficacy of prostate cancer detection by trained dogs on human urine samples.

8 Feb 2011

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen, or PSA.

16 Dec 2010

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced the publication of new research in the Canadian Urological Association Journal (CUAJ) showing that large-scale deletions in mitochondrial DNA (mtDNA) can indicate cellular changes that are associated with the development of cancer.

5 Oct 2010

New predictive test to identify aggressive prostate cancer

S. Mark Redwood, M.D., chief of the Department of Urology at Sinai Hospital, is using a state-of-the-art predictive prostate cancer test called Prostate Px+ to better understand the aggressiveness of each individual patient's cancer and how best to treat it.

29 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

CINJ experts available for discussion during National Prostate Cancer Awareness Month

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, treatments and prevention options surrounding prostate cancer during September, which is National Prostate Cancer Awareness Month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

15 Sep 2010

Patients are not presented with information about prostate cancer treatment options: Urologists

At the recent meeting of the American Urological Association in San Francisco, researchers presented studies regarding the decision making process men go through when considering proposed prostate cancer treatments. Dr. Vorstman, renowned Florida urologist, believes these studies would have more meaning if patients were presented with information about prostate cancer treatment options in a different fashion.

7 Jul 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology meeting, the world largest urology event, held in Barcelona, Spain, with 14,000 registrants.

22 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.

8 Mar 2010

Prostate Biopsy News and Research

Further Reading

UIC study reveals potential of lycopene in prostate cancer prevention among African American men

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

Men with high DHA levels may face risk of developing aggressive prostate cancer

Mitomics introduces new test to detect prostate cancer

Prostate Oncology Specialists introduces new blog for patients

Debate continues regarding certain medical tests

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

Study shows dogs can be trained to detect PCa by smelling urine

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

mtDNA deletion: New biomarker for identifying malignant prostate cancer

New predictive test to identify aggressive prostate cancer

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

CINJ experts available for discussion during National Prostate Cancer Awareness Month

Patients are not presented with information about prostate cancer treatment options: Urologists

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News